How advances in drug discovery are changing the path from research to clinical trials

Advances in computational drug design and regulatory shifts, particularly the FDA Modernization Act 2.0, are accelerating the drug discovery pipeline by reducing reliance on animal testing and shifting more scientific validation to early human trials. These changes require sponsors to generate more human-relevant preclinical data and integrate biomarker-driven studies early, increasing early trial complexity but improving go/no-go decisions later.

This Wire brief sits within Fusion42's coverage of Drug Discovery.